Precision Medicine

Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Thumbnail

2014 HCLF in review: Energizing and insightful

The 2014 Healthcare Leadership Forum has concluded in Chicago, and participants were energized! Produced by Clinical Innovation + Technology’s parent company TriMed Media Group and sponsored by Elsevier Clinical Solutions, there was a palpable buzz in the air during and immediately following the gathering.

Wal-Mart elimination of insurance may signal move to single-payer model

Wal-Mart’s elimination of health insurance coverage for 30,000 part-time workers may actually be a boom to more progressive health reform models like a single-payer system, according to Salon.

Texas Ebola patient dies, another may be infected

On the same day that Thomas Eric Duncan died of Ebola, an urgent care clinic in Frisco, Texas is reporting that another patient is exhibiting symptoms of the virus, reports Modern Healthcare.

HIMSS and AVIA Launch HX360™ to Improve Health Care Delivery through Emerging Technologies

CHICAGO, Oct. 8, 2014-- Today, Healthcare Information and Management Systems Society (HIMSS) and AVIA announced HX360™, a new co-developed initiative. HX360 was created to improve the way that health care is delivered by both inspiring and facilitating the adoption and use of next generation (non-EHR Platform) technologies by provider organizations, in areas where health system executives are passionate to combine the right mix of resources, processes and technologies.

Surescripts and Epic Improve Prescribing Accuracy and Efficiency with EHR-Integrated Electronic Prior Authorization

ARLINGTON, Va.--Surescripts, the nation’s largest health information network, and Epic, the leading developer of software for mid-size and large medical groups, hospitals and integrated healthcare organizations, are working together to improve the accuracy and efficiency of the prescribing process by offering Surescripts’ CompletEPA® for medication prior authorization to Epic electronic health records (EHR) users.

Global Home Healthcare Market To Grow Owing To Increased Use Of Healthcare Technologies From 2014 To 2020: Grand View Research, Inc.

San Francisco, California, September 30, 2014 -- The global market for home healthcare is expected to reach USD 355.3 billion by 2020, growing at an estimated CAGR of 7.8% from 2014 to 2020, according to a new study by Grand View Research, Inc.

Thumbnail

Geisinger telemonitoring program achieved 3:1 ROI

A telemonitoring program implemented at Geisinger Health System led to significant reductions in all-cause 30-day and 90-day readmissions. Moreover, for every $1 spent to implement the program, there was approximately $3.30 in savings, according to a study published in Population Health Management.

ProVation Order Sets Named Overall Best Performer Among Order Set Solutions in KLAS Clinical Decision Support Report

Oct. 7, 2014- Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that ProVation® Order Sets, powered by UpToDate® Decision Support, was ranked by KLAS Research as having the best overall performance among order set solutions in its report, “CDS Order Sets and Care Plans 2014: Choosing the Best Option.” This marks the third time ProVation Order Sets has achieved top ranking in the annual report on the clinical decision support solutions market.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.